Vical könnte zum echten Homerun werden

Das Biotech-Unternehmen Vical sei im Bereich neuer Krebstherapien tätig. Das Medikament Allovectin-7, das in der Behandlung von metastierenden Melanomen Verwendung finden solle, sei derzeit der größte Hoffnungsträger in der Produktpipeline der Gesellschaft.

http://www.ad-hoc-news.de/...echten-homerun-werden--/de/News/21574183  

habe mir eine erste Position ins Depot gelegt.
Wie bei allen Biotech-Unternehmen besteht auch hier die Gefahr bei negativen Studienergebnissen massive Kurseinbrüche hinnehmen zu müssen. Dafür ist auch das Potential, bei positiven Ergebnissen, entsprechend gross.
Meiner Meinung nach ist das Chance / Risko - Verhältnis bei Vical ganz gut.

Hier noch der Link zur hompage:
http://www.vical.com/  

"Vical (NASDAQ:VICL), the developer of gene-based pharmaceutical products was initiated with a Buy at Dawson James and a target price of $7 per share. The firm said shares trade at a 50% discount to comparable companies focused on immunotherapeutics, they believe shares are undervalued and represent an attractive entry point at current prices. Analysts also noted Vical has three Phase III Stage Products with blockbuster potential."

http://www.tradershuddle.com/2010090777767/...v-mtd-tmo-vicl-wat.html  

SAN DIEGO, Sep 8, 2010 (GlobeNewswire via COMTEX) -- Vical Incorporated /quotes/comstock/15*!vicl/quotes/nls/vicl (VICL 3.40, +0.20, +6.25%) today announced that the company's President and Chief Executive Officer, Vijay B. Samant, will provide an overview of the company's technologies, development programs, and strategic partnerships at the Stifel Nicolaus 2010 Healthcare Conference (Boston, September 15 -- 17).

A webcast of Mr. Samant's presentation at the conference will be available live (11:30 a.m. EDT on Wednesday, September 15) and archived through the Events page in the Investors section of the Vical website at www.vical.com.

http://www.marketwatch.com/story/...e-2010-09-08?reflink=MW_news_stmp  

hier noch etwas verspätet die News welche den Kurssprung letzter Woche ausgelöst hat:


UPDATE 1-Vical says DNA vaccine meets goals of mid-stage trial

Mon Sep 13, 2010 8:46am EDT

* Vaccine for cytomegalovirus in cell transplant patients

* Says TransVax meets key goals in mid-stage trial

* Shares up 6 pct premarket

Sept 13 (Reuters) - Vical Inc (VICL.O) said a mid-stage trial showed its cytomegalovirus vaccine was safe and effective in blood-cell transplant patients with a weak immune system.

The study showed the DNA vaccine, TransVax CMV, had the ability to drive effective immune responses in patients whose immune system has been impaired by disease or treatment, the company said.

Vical's shares were up 6 percent at $4.08 in trading before the bell. They have gained 22 percent in the last three months. (Reporting by Shravya Jain in Bangalore; Editing by Vinu Pilakkott)

http://www.reuters.com/article/idUSSGE68C0G820100913  

über den 2.80€. Jetzt nur noch etwas Geduld und eine weitere, positive Meldung (und die wird m.M.n. früher oder später kommen), und wir werden über 3€ stehen.
Weiterhin viel Erfolg mit Vical...  

hat jemand eine ahnung warum der kurs der kurs bei realtime nur noch 1,80 € anzeigt, es sind doch keine neuen news draußen oder etwa doch???  

gibts hier news???
übel übel  

http://www.bloomberg.com/news/2010-09-22/...-endpoint.html?cmpid=yhoo

Mann, dass diese Biotechs immer dermassen übertreiben müssen.
Vical hat doch im eigentlichen Sinne gar nichts damit zu tun.
Sanofi Aventis versemmelts und Vical ziehts genauso mit runter.
Da bringt Stopp-Loss überhaupt nichts.
Mich hats eiskalt erwischt!
Die Frage ist jetzt nur... sollte man gleich  nachkaufen oder erst mal warten bis Vical
sich von dem Schlag in die Magengrube erholt hat?  

naja, mit Vorsicht zu geniessen.  

tja, so schnell kann es bei Biotech-Buden halt gehen. Ich für meinen Teil bleibe hier mit meinem kleinen Invest nach wie vor drin. Das Risiko, aber auch die Chancen, sind mir bekannt und die nehme ich bewusst in Kauf. Hier nochmals eine Meldung bezüglich dem negativen Testergebnis von Sanofi Anetis sowie eine mögliche Erklärung zum Kursrückgang bei Vical:

"... THE BIG PICTURE: San Diego's Vical does not have any products on the market, and makes its revenue from licenses and royalty payments along with contracts and grants. NV1FGF had advanced through earlier stages of testing, but the failure means it may never be approved and Vical won't receive more revenue or royalties...."

http://www.businessweek.com/ap/financialnews/D9ID5DL00.htm  

 

Vical's Stock Offering Priced At Steep 22% Discount

Vical Inc. (VICL) released terms of its planned stock sale, with the biopharmaceutical development company becoming the latest in its sector selling equity.

It didn't disclose any estimates when disclosing the effort Thursday. On Friday, it said it will sell at least 15 million shares at $2.25 each, a steep 22% discount to Thursday's closing price. Discounts above 10% are uncommon.

There are about 56 million shares outstanding. Shortly after the market opened, the stock slumped 18% to $2.36.

Vical, which develops gene-based treatments for cancer as well as vaccines for infectious diseases, hasn't said what the proceeds would go toward. But a host of drug developers have been tapping the market with fresh equity to raise money to fund research efforts.

The company's stock was down 23% this week through Thursday as the blood-vessel drug on which Vical formed a partnership with French drug company Sanofi-Aventis SA (SNY, SAN.FR) didn't meet the primary endpoint of a late-stage trial.

http://online.wsj.com/article/BT-CO-20100924-706299.html  

schliesslich hat Vical auch noch andere Produkte in der Pipeline:

"... The outlook for Vical is the least clear of this group. The company's drug (licensed to Sanofi-Aventis (NYSE: SNY)) did not fare well in tests to see if it could create new blood vessels to help increase blood flow to distressed limbs. But the company has several promising drugs that are being tested earlier in the clinical process, and some analysts think this latest setback will be forgotten if those other drugs can make headway in clinical trials..."

http://www.streetauthority.com/news/...ptembers-biggest-losers-456616  

"... Biopharmaceutical Vical has been giving investors a rollicking ride as well. In what looks like the death throes of the company following a report that a drug it was developing with sanofi-aventis (NYSE: SNY) to restore blood vessel growth in damaged limbs was reported as being no better than a placebo in late-stage tests, shares plummeted, soared, and fell again all in the space of a week.

While many CAPS members are siding with member tenmiles that the risk-reward ratio is in Vical's favor, DudeManBroChief figures the stock will rise by an appreciable amount between now and the results being released for Allovectin-7 next year.

Look for this stock to spike in mid-2011 before results are revealed for the phase III trial of Allovectin-7 in melanoma..."

http://www.fool.com/investing/general/2010/10/04/...-are-no-dogs.aspx  

Vical Updates TransVax(TM) CMV Vaccine Program at World Vaccine Congress

LYON, France, Oct. 5, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company's Executive Vice President of Product Development, Alain P. Rolland, Pharm.D., Ph.D., is presenting detailed results from the company's recently completed Phase 2 trial of its TransVax™ therapeutic vaccine designed to control reactivation of cytomegalovirus (CMV) in transplant patients. Dr. Rolland is scheduled to present at 5:40 p.m. CEST today at the World Vaccine Congress (Lyon, France, October 4 – 7).

http://www.globenewswire.com/newsroom/news.html?d=202936  

Vical to Manufacture DNA Vaccines for Advanced Development by HIV Consortium
SAN DIEGO, Oct 7, 2010 (GlobeNewswire via COMTEX) -- Vical Incorporated /quotes/comstock/15*!vicl/quotes/nls/vicl (VICL 2.25, -0.01, -0.44%) today announced that the company has agreed to manufacture plasmid DNA (pDNA) vaccines against HIV under a $2.4 million contract with the IPPOX Foundation, a collaborating institution for the Poxvirus Vaccine Regimen Design (PVRD) led by the Centre Hospitalier Universitaire Vaudois (CHUV) under the auspices of the Collaboration for AIDS Vaccine Discovery (CAVD).

A pDNA prime/poxvirus boost vaccine approach has been developed since 1998 by the EuroVacc program and currently the focus of the CAVD's Poxvirus T-cell Vaccine Discovery Consortium. The DNA/poxvirus approach has been tested in multiple Phase 1 and 2 clinical trials in Europe and has shown to be highly immunogenic. The current project is investigating whether the 2nd generation DNA/poxvirus vaccine approach combined with novel immunization strategies can induce increased and balanced Env, Gag, Pol and Nef HIV-1-specific T-cell responses in humans. Successful outcomes in the human studies could lead to further clinical development of the DNA and poxvirus vaccine candidates in Africa.

Vical will produce individual plasmids encoding selected portions of the Env and Gag antigens, and one plasmid encoding selected portions of the Pol and Nef antigens. These plasmids will be combined and delivered as a single vaccine. Delivery is expected to be completed in the fourth quarter of 2010.

http://www.marketwatch.com/story/...m-2010-10-07?reflink=MW_news_stmp  

verdammt komischer kursverlauf hier ... gute news aber das ding will nicht steigen ... immer dieses zick zack muster im tageschart ... werde weiter halten mal sehn was passiert .  

am Montag sollte eigentlich was gehen:

Vical lands deal to make experimental HIV vaccine

By Keith Darcé
Saturday, October 9, 2010 at 3 p.m.

Vical of San Diego said it will receive $2.4 million to manufacture an experimental DNA vaccine to treat HIV for a Swiss research institute.

The IPPOX Foundation, a research institute within the Centre Hospitalier Universitaire Vaudois in Lausanne, Switzerland, has been testing an early generation of the vaccine for several years.

The researchers plan to use the second-generation vaccine produced by Vical in combination with new immunization strategies in early stage clinical trials.

If the tests are successful, the vaccine could be further developed for use in Africa, where HIV rates have reached epidemic proportions, infecting more than 22 million people.

Vical, which also works on its own experimental drug candidates, said the vaccine should be delivered by the end of the year.

http://www.signonsandiego.com/news/2010/oct/09/...mental-hiv-vaccine/  

erneut keine Reaktion auf die Meldung. Hier wiegt wohl die Kapitalerhöhung mehr als die zuletzt erfolgten positiven Meldungen.
Abwarten und Teetrinken...  

die Hoffnung ist noch nicht gestorben:

"NV1FGF - Top 10 Phase III Failures
October 21, 2010 — 7:09am ET | By John Carroll

Tools
Subscribe
Email
Print
Comment
Contact Author
Reprint
The drug: NV1FGF
The disease: Critical limb ischemia
The companies: Sanofi-Aventis and Vical

Sanofi-Aventis had high hopes for NV1FGF and the Tamaris Phase III study was designed to show that it was better than a placebo in preventing death and disease from critical limb ischemia. More than 500 patients were enrolled to see if investigators could find statistically significant signs that the drug could spur the growth of new blood vessels, helping patients with limbs damaged by embolism or thrombosis.

Vical, which had handed off the development of the drug to Sanofi in a licensing agreement, saw its shares plummet by 32 percent in September. Even Sanofi shares were dinged by the "disappointing" outcome.

When Sanofi stepped in, its researchers had solid mid-stage data in hand indicating that the drug could help prevent the more than 150,000 amputations that occur every year in the U.S. and Europe due to critical limb ischemia. Next months, they'll get a chance to explain what went wrong at the American Heart Association Congress."

http://www.fiercebiotech.com/special-reports/...10-phase-iii-failures  

am 09.11. kommen mal wieder neue Zahlen auf den Tisch:

Vical Announces News Release Schedule for Third Quarter 2010 Financial Results and Plans to Host Analyst and Investor Day in New York
SAN DIEGO, Nov 2, 2010 (GlobeNewswire via COMTEX) -- Vical Incorporated /quotes/comstock/15*!vicl/quotes/nls/vicl (VICL 2.14, -0.02, -0.93%) today announced that the company will report financial results for the three months and nine months ended September 30, 2010, before the opening of trading on Tuesday, November 9.

Analyst and Investor Day

In lieu of its usual financial results conference call and webcast, Vical is hosting an Analyst and Investor Day event in New York for invited analysts and institutional investors beginning at 5:00 p.m. EST on Tuesday, November 9. A webcast of the event will be available live and archived through the Events page in the Investors section of the Vical website at www.vical.com. For further information, contact Vical's Investor Relations department by phone at (858) 646-1127 or by e-mail at info@vical.com.
..."

http://www.marketwatch.com/story/...k-2010-11-02?reflink=MW_news_stmp  

@Hoomer  

so iss es.... (leider).
Ich wart nun noch die Präsentation vom 09.11. ab. Neben den Zahlen erwarte ich auch einen Ausblick für das nächste Jahr. Und je nach dem, werde ich die Verlust halt realisieren (müssen). Zum Glück bin ich hier bloss mit einer sehr kleinen Position eingestiegen. Aber trotzdem, der Verlulst ist nicht schön.
So ist es halt bei solchen Werten. Verlaufen die Tests positiv, kann man gewaltige Gewinne einfahren. Und im anderen Fall, sehen wir an diesem Beispiel am besten wie's laufen kann....  

mit meiner Epigenomics...sehr nervig warte nur noch bis ich PLUS/MINUS 0 bin und dann umschichten...